Sanjiv Anand
Nephrology · South Salt Lake, UTNPI 1992991921
Payments from drug & device makers
Across 417 payments — averaging $2588.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$459K
- Akebia Therapeutics Inc$190K
- Astrazeneca UK Limited$134K
- Bayer$84K
- Vertex$64K
- Eli Lilly$60K
- plus $89K from 14 others
Across 3 payments — averaging $3227.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$10K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 133 | $458,760 |
| Akebia Therapeutics Inc | 182 | $190,195 |
| Astrazeneca UK Limited | 3 | $133,792 |
| Bayer | 22 | $83,613 |
| Vertex | 2 | $64,153 |
| Eli Lilly | 2 | $60,192 |
| Novartis | 40 | $50,753 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $23,744 |
| Calliditas Therapeutics US Inc. | 13 | $13,003 |
| Boehringer Ingelheim International GmbH | 6 | $365 |
| One Lambda, Inc. | 1 | $250 |
| Sanofi US Services Inc. | 1 | $190 |
| Biogen | 1 | $101 |
| ANI Pharmaceuticals, Inc. | 1 | $82 |
| Veloxis Pharmaceuticals, Inc. | 1 | $36 |
| GSK | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| Exelixis Inc. | 1 | $24 |
| Renalytix AI, Inc. | 1 | $12 |
How this compares
$1,079,356 in reported general payments places this provider in the 95th percentile of 74 nephrology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in South Salt Lake
- Sey LauSouth Salt Lake$3K
- Arasu GopinathSouth Salt Lake$3K
- Donald MorrisSouth Salt Lake$3K
- Ruth IndahyungSouth Salt Lake$3K
- Kevin JansenSouth Salt Lake$3K
- Roman ShingarevSouth Salt Lake$2K
- Indraneel MogaralaSouth Salt Lake$2K
- Dave TienSouth Salt Lake$2K
- Landon DicksonSouth Salt Lake$2K
- Jeff BarklowSouth Salt Lake$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.